INTRODUCTION AND OBJECTIVES: Until the early 2000s, ipsilateral adrenalectomy at the time of radical nephrectomy was genrally recommended except in small tumors of the lower pole. In the current era, as radical nephrectomy sparing the adrenal gland has become the gold standard, the incidence of metachronous adrenal metastases has increased. However, to date no study has aimed to assess the outcomes of adrenalectomy for metastasis of renal cell carcinoma (RCC). The aim of this study was to report the outcomes of adrenalectomy for metastasis of RCC.
INTRODUCTION AND OBJECTIVES: Until the early 2000s, ipsilateral adrenalectomy at the time of radical nephrectomy was genrally recommended except in small tumors of the lower pole. In the current era, as radical nephrectomy sparing the adrenal gland has become the gold standard, the incidence of metachronous adrenal metastases has increased. However, to date no study has aimed to assess the outcomes of adrenalectomy for metastasis of renal cell carcinoma (RCC). The aim of this study was to report the outcomes of adrenalectomy for metastasis of RCC.
METHODS: All adrenalectomies for suspected adrenal metastases of RCC performed in seven centers between 2006 and 2016 were included in a retrospective study. The adrenalectomies performed at the time of ipsilateral nephrectomy were excluded. Recurrence-free survival (RFS) and specific survival (CSS) were estimated using the KaplanMeier method. Prognostic factors of CSS were sought by univariate and multivariate Cox regression analyzes.
RESULTS: Forty-eight patients were included. Mean tumor size was 40.8 mm. Histology of the primary tumor was clear cell renal cancer in most cases (94.8%). Metastases were unique in 77% of patients. Metastases were metachronous in 77% of cases and occurred after a mean interval of 8.1 months. The average hospital stay was 5.4 days. The rate of positive margins was 9%. The complication rate was 23.9% but with only three major complications (Clavien> 2; 6.2%). After a median follow up of 23 months, Estimated RFS and CSS rates at 5 years were 18.3% and 97.5% respectively. The only prognostic factor associated with CSS was the absence of other metastases at the time of adrenalectomy (OR ¼ 6.1; p ¼ 0.03).
CONCLUSIONS: In this multicenter study, adrenalectomy for adrenal metastasis of RCC offered satisfactory perioperative outcomes. Recurrence of disease was relatively common (5 year-RFS: 18.3%; only prognostic factor ¼ single metastasis) but CSS was similar to those observed after partial nephrectomy for small renal tumors (5 year-CSS: 97.5%).
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MP37-14 ONCOLOGICAL OUTCOMES OF RADICAL NEPHROURETERECTOMY WITH AND WITHOUT SYNCHRONOUS IPSILATERAL ADRENALECTOMY
benoit peyronnet*, quentin alimi, gregory verhoest, lauranne tondut, vivien graffeille, anna goujon, romain mathieu, andrea manunta, solene-florence kammerer-jacquet, nathalie rioux-leclercq, karim bensalah, rennes, France INTRODUCTION AND OBJECTIVES: During the past decade, the role and indications of adrenalectomy as part of radical nephrectomy for renal cell carcinoma have been clearly defined. In contrast, the impact of synchronous adrenalectomy during radical nephroureterectomy for upper tract urothelial carcinoma (UTUC) has never been evaluated. The aim of this study was to assess the impact of adrenal resection during radicla nephroureterectomy for UTUC.
METHODS: The charts of all patients who underwent nephroureterectomy for upper tract urothelial carcinoma in a single-center between 1994 and 2014 were retrospectively reviewed. Patients were divided into two groups: synchronous ipsilateral adrenalectomy (A) and no synchronous ipsilateral adrenalectomy (NA). Perioperative outcomes (operative time, complications, positive margins, ... ) were compared between the 2 groups using ?2 and Mann-Whitney tests. Survival outcomes were estimated using the Kaplan-Meier method. The impact of synchronous adrenalectomy on cancer-specific-survival (CSS) and recurrence-free survival (RFS) was evaluated using the logrank test.
RESULTS: One hundred and forty five patients were included in the study. Among them 21 had synchronous ispilateral adrenalectomy but only one adrenal specimen was invaded by the UTUC on final pathology (4.8%) and this invasion was diagnosed on preoperative imaging. Synchronous adrenalectomy had no impact in terms of operative time (265 vs. 241 min; p ¼ 0.22), transfusion rate (20% vs. 18.4%; p ¼ 0.87), complication rate (38.1% vs. 39.8%; p ¼ 0.89) or positive margins (9.6% vs. 13.2%; p ¼ 0.64). CSS (79.6% vs. 62.8%; p ¼ 0.18) and RFS (70% vs. 56.6%; p ¼0.33) at 5 years were comparable between both groups.
CONCLUSIONS: In this single-center series, adrenal resection during nephroureterectomy for UTUC did not increase perioperative morbidity but did not provide oncologic benefit. Adrenal invasion by UTUC was rare (4.8%) and diagnosable on preoperative imaging. Hence, routine ipsilateral adrenalectomy during radical nephroureterectomy may not be indicated. 
MP37-15 CONTRALATERAL ADRENAL THICKNESS PREDICTS THE DURATION OF PROLONGED POST-SURGICAL STEROID REPLACEMENT FOR SUBCLINICAL CUSHING SYNDROME
Yusuke Imamura*, Masahiro Sugiura, Satoshi Yamamoto, Tomokazu Sazuka, Miki Fuse, Kazuyoshi Nakamura, Shinichi Sakamoto, Koji Kawamura, Takashi Imamoto, Akira Komiya, Tomohiko Ichikawa, Chiba, Japan INTRODUCTION AND OBJECTIVES: Adrenal insufficiency after adrenalectomy in patients with cortisol secreting adenomas is potentially critical if not treated. Therefore, patients who undergo adrenalectomy for subclinical Cushing syndrome (SCS) require postsurgical glucocorticoid replacement treatment. By contrast, the total duration of steroid replacement is still controversial and varies among patients. Here we analyzed pre-treatment various factors potentially affecting the duration of post-surgical steroid replacement in patients after laparoscopic adrenalectomy for SCS.
METHODS: This retrospective analysis included 66 patients who underwent unilateral laparoscopic adrenalectomy for SCS between March 2005 and May 2016 at Chiba University Hospital. Adrenal tumor and contralateral adrenal sizes together with various clinical factors were studied in association with the duration of post-surgical steroid replacement. Adrenal tumor and contralateral adrenal sizes were measured at the level of maximum size of adrenal glands using CT scan. Cox's proportional hazard model was used for the statistical analysis.
RESULTS: All 66 patients treated post-surgical steroid replacement after adrenalectomy. Median duration of the steroid treatment was 6 months. Median age of the patients was 59 years. Among 66 patients, 37 cases had left adrenal tumor and 29 cases had right tumor. Median size of the tumor was 26.5mm. Median operation time was 175 minutes. Only 1 case converted to open surgery. When assessing the duration of post-surgical steroid replacement, maximum tumor diameter (MTD) > 26.5mm (HR 1.92, P ¼ 0.0493) and contralateral adrenal thickness (CAT) < 6.3mm (HR 4.38, P < 0.0001) were significant predictors of prolonged post-surgical steroid treatment on univariate analysis. On multivariate analysis, CAT < 6.3mm (HR 4.04, P < 0.0001)was the only independent predictive factor for the prolonged post-surgical steroid replacement.
CONCLUSIONS: Contralateral adrenal thickness was the significant predictive factor for the duration of post-surgical steroid replacement in SCS patients. Pre-surgical assessment in the imaging may help clinicians determine the total duration of steroid therapy after adrenalectomy.
